RxDoctor Payments Data

Zhe Zheng

Cardiovascular Disease · Baton Rouge, LANPI 1083879175

Payments from drug & device makers

$967in general payments, 2019–2025

Across 29 payments — averaging $33.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$205
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$203
  • Kestra Medical Technology Services, Inc.$170
  • Medtronic$101
  • Cvrx, Inc.$96
  • Novartis$77
  • plus $115 from 5 others

What the payments were for

  • Food & beverage$967100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$967 in reported general payments places this provider in the 25th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$139,252
Medicare patients
1,193
Services billed
2,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,004$929,072
Repatha SureclickEvolocumab897$520,381
EntrestoSacubitril/Valsartan249$233,869
XareltoRivaroxaban138$147,305
JardianceEmpagliflozin122$102,080
Praluent PenAlirocumab154$75,834
RybelsusSemaglutide26$37,774
FarxigaDapagliflozin Propanediol32$27,873
OzempicSemaglutide18$22,884
BrilintaTicagrelor35$22,696
WegovySemaglutide11$15,495
Metoprolol Succinate1,557$13,890
Ranolazine ErRanolazine189$9,690
Atorvastatin Calcium799$7,709
Losartan Potassium747$5,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$929,0721,004 claims
NovartisEntresto$77$233,869249 claims
Johnson & JohnsonXarelto$13$147,305138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →